Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography

O. Clyde Hutchinson; David R. Collingridge; Henryk Barthel; Pat M. Price; Eric O. Aboagye

doi:10.2174/1381612033455251

Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography

O. Clyde Hutchinson, David R. Collingridge, Henryk Barthel, Pat M. Price, Eric O. Aboagye

Research output: Contribution to journal › Article › peer-review

Abstract

Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.

Original language	English
Pages (from-to)	931-944
Number of pages	13
Journal	Current Pharmaceutical Design
Volume	9
Issue number	11
DOIs	https://doi.org/10.2174/1381612033455251
Publication status	Published - 2003

Keywords

Animals
diagnostic use: Antineoplastic Agents
Drug Resistance, Neoplasm
Humans
drug therapy: Neoplasms
Radioactive Tracers
diagnostic use: Radiopharmaceuticals
Tomography, Emission-Computed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/1381612033455251

Cite this

@article{825950e0c075413ea2258433f48a5c89,

title = "Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography",

abstract = "Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.",

keywords = "Animals, diagnostic use: Antineoplastic Agents, Drug Resistance, Neoplasm, Humans, drug therapy: Neoplasms, Radioactive Tracers, diagnostic use: Radiopharmaceuticals, Tomography, Emission-Computed",

author = "Hutchinson, \{O. Clyde\} and Collingridge, \{David R.\} and Henryk Barthel and Price, \{Pat M.\} and Aboagye, \{Eric O.\}",

year = "2003",

doi = "10.2174/1381612033455251",

language = "English",

volume = "9",

pages = "931--944",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science Publishers",

number = "11",

}

TY - JOUR

T1 - Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography

AU - Hutchinson, O. Clyde

AU - Collingridge, David R.

AU - Barthel, Henryk

AU - Price, Pat M.

AU - Aboagye, Eric O.

PY - 2003

Y1 - 2003

N2 - Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.

AB - Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.

KW - Animals

KW - diagnostic use: Antineoplastic Agents

KW - Drug Resistance, Neoplasm

KW - Humans

KW - drug therapy: Neoplasms

KW - Radioactive Tracers

KW - diagnostic use: Radiopharmaceuticals

KW - Tomography, Emission-Computed

UR - https://www.scopus.com/pages/publications/0037240517

U2 - 10.2174/1381612033455251

DO - 10.2174/1381612033455251

M3 - Article

SN - 1381-6128

VL - 9

SP - 931

EP - 944

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

IS - 11

ER -

Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this